Menopause constitutes a sizable population of the adult woman´s life, and it is reasonable to consider that most women will benefit from hormone replacement therapy. Also, it is important to realized that cardiovascular disease and bone fracture are a major cause of morbidity and death in the menopausal patient.
To study the effects of different types of progesterone- on lipoprotein metabolism and bone metabolism, we treated two groups of postmenopausal women with for three weeks with conjugated equine estrogen 0.625 mg per day and different sequential estrogen-Progesterone regimens as followes: Group I received medroxyprogesterone acetate, 2.5 mg per day, from day 14 to day 25 of the cycle; Group II, medroxyprogesterone acetate, 5 mg per day.
The data demonstrated a beneficial effect in lipoprotein profiles, that total cholesterol decreased in two groups by 8.6 to 11.7 percent from the baseline values.
Low density lipoprotein cholesterol decrease in two groups by 18.5 (group I) and 32.7 (group II) percent in post HRT 12 months. High density lipoprotein cholesterol increase during treatment by smaller in 5.3 percent and higher in 27 percent in both groups. Triglyceride increase during initial 6 months period (6.5-283 percent) and decrease during post 12 months period in both groups. Lumbar BAD and Femur BMD were decrease during 6 months period and increase during later 6 months in Group I, but in Group II results shows reciprocal change compared with Group I.
Our result suggest that medroxyprogesterone acetate especially 5 mg per day have the beneficial effect of postmenopausal estrogen treatment on HDL-cholesterol and so, the favorable lipoprotein profile offer protection to the cardiovascular system and medroxyprogesterone acetate was no adverse effect to bone mineral density in postmenopausal HRT women.
|